Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

This RCT demonstrated that combination of copanlisib plus rituximab improved progression-free survival vs placebo plus rituximab (n=458; 21.5 vs 13.8 months; HR 0.52; 95% CI 0.39–0.69; p<0.0001) but with a higher number of serious adverse events (47% vs 18%).

Source:

The Lancet Oncology